<DOC>
	<DOCNO>NCT02771379</DOCNO>
	<brief_summary>This study multicentre , prospective , non-interventional post-authorisation safety study ( PASS ) clinical outcome patient LHON treat Raxone® . No medication provide part study . Raxone® obtain commercial channel .</brief_summary>
	<brief_title>Post Authorisation Safety Study With Raxone LHON Patients</brief_title>
	<detailed_description />
	<mesh_term>Optic Nerve Diseases</mesh_term>
	<mesh_term>Optic Atrophy , Hereditary , Leber</mesh_term>
	<mesh_term>Idebenone</mesh_term>
	<criteria>Patient prescribe Raxone® treatment LHON ; Patient complete Informed Consent Form ( ICF ) indicate he/she ( legally acceptable representative ) inform pertinent aspect study agree participate study ; Patient participate interventional study . No explicit exclusion criterion exist avoid selection bias allow documentation routine clinical practice .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>